Conveners
Ovarian cancer (PART I)
- Uwe Haberkorn (University of Heidelberg)
- Clemens Decristoforo (Department of Nuclear Medicine, Medical University Innsbruck)
Ovarian cancer is the 8th most common cancer in women and the 5th most common reason for cancer death. There is no recognized screening method and ovarian cancer is most often diagnosed at an advanced stage. I will give a short background on epidemiology of epithelial ovarian cancer as well as on its diagnosis and genetic background. Then, we will discuss current standard treatment which...
Ovarian cancer is the most lethal gynecologic malignancy and it has high rate of recurrence justifying the development of new therapeutic tools. Our project aims at developing new radiopharmaceuticals and innovative route of administration to target the small volume residual disease after complete cytoreductive surgery of peritoneal carcinomatosis on preclinical models. We use internalising...
Aim. To assess the feasibility of mouse-specific, microPET- based dosimetry of an antibody labelled with 152Tb. Image-based absorbed dose estimates were compared with dosimetry results obtained from the extrapolation to 152Tb of a classical biodistribution experiment using the same antibody fragment labelled with 111In.
Methods. The scFv78-Fc fusion protein targeting TEM-1 was...
Introduction: Targeted radionuclide therapy using 161Tb is a promising approach for β- and Auger electron therapy.1 Moreover, the availability of the diagnostic radionuclides 152/155Tb is of interest in a theranostic setting.2-4 Heat-sensitive biomolecules (e.g. antibody fragments, etc.) are increasingly being used as carriers in radiometal-based radiopharmaceuticals. These molecules,...
Objectives: Targeted α-radionuclide therapy is a promising cancer therapy that allows targeted irradiation of primary tumour and its metastases. 213Bi-DOTATATE targeting the somatostatin receptor has been reported to delay growth in small and large volume endocrine tumours in mice (1,2). However, DOTA chelator has poor labelling kinetics and radiochemical purity with Bismuth-213. It...
The TEM1/endosialin is a receptor over-expressed in several human solid tumours and silenced in normal adult tissues, representing a suitable and potentially safe target for radioimmunotherapy of sarcoma.1,2 Taking advantage of the very fast in vivo kinetic of the click reaction between tetrazines (Tz) and trans-cyclooctene (TCO), we intent to explore a pre-targeting approach for the...
